
Questions and expectations swirl as Monarez steps into director's role at CDC
Vaccines
Chronic diseases
Disability issuesFacebookTweetLink
Follow
Dr. Susan Monarez will be sworn in as director of the US Centers for Disease Control and Prevention on Thursday, and she's taking the reins at a perilous time for the agency.
The CDC has lost nearly a quarter of its staff since January, thanks to massive workforce cuts at federal health agencies. The Trump administration's proposed budget for the fiscal year 2026 would slash the agency's funding by more than half. And under a proposed reorganization, the agency stands to lose more of its programs: Some are set to be moved to a new Administration for a Healthy America while others, such as the National Center for Chronic Disease and Health Promotion, would be eliminated altogether.
All this is playing out as US Health and Human Services Secretary Robert F. Kennedy Jr., who has long promoted misinformation about vaccines, has moved to undermine longstanding federal policies and processes that support vaccination in the United States.
Kennedy has also throttled communications coming out of federal health agencies, including the CDC, all but silencing its scientists amid the worst measles outbreak in the US in three decades.
Many at the agency and in the wider public health world are wondering whether Monarez will prove to be a savior or a sycophant.
Morale among agency staff is bleak, according to one CDC official who spoke on the condition that they not be named for fear of reprisals.
Staffers are feeling unsure about what Monarez's confirmation means, the official said. Many see her as a good scientist and someone with experience in leadership positions at federal agencies.
But they also wonder whether she'll be constrained by Kennedy, the official said.
Monarez's tenure in government spans Republican and Democratic administrations. Before coming to the CDC in January, she was deputy director for the Advance Research Projects Agency for Health, or ARPA-H, and was founding director of the Center for Innovation at the Health Resources and Services Administration. She held other leadership positions at the Department of Homeland Security and the Biomedical Advanced Research and Development Authority.
In her confirmation hearing, Monarez described herself as the daughter of a dairy farmer from rural Wisconsin who attended state schools and paid her own way through college, eventually earning a Ph.D. in microbiology and immunology. She said that her research was focused on two diseases, African sleeping sickness and toxoplasmosis, and that she was drawn to public health because treatments for those diseases remain limited but public health interventions have reduced the impact of the diseases.
Under questioning by senators, Monarez seemed to distance herself from Kennedy on two issues: vaccines and fluoride.
In response to questions from Sen. Bernie Sanders, an independent from Vermont, about the US ending its support for the Global Alliance for Vaccines and Immunization, Monarez said, 'I think vaccines save lives. I think that we need to continue to support the promotion and utilization of vaccines.'
When Sanders asked whether she agrees that there is no scientific proven link between vaccines and autism, Monarez said, 'I have not seen a causal link between vaccines and autism.'
Regarding fluoride, Monarez told Sen. Angela Alsobrooks that she considered it 'an important component to oral health. … The direct application can be very valuable.'
Alsobrooks asked about fluoridation of public drinking water, including in Monarez's own town. 'They have fluoridation there. Is it safe for families, the water in Potomac, Maryland?'
'I believe the water in Potomac, Maryland, is safe,' Monarez answered.
One staffer who worked under Monarez at ARPA-H described her as a quiet presence. She wasn't the type of manager who is an active presence on Slack or email, they said.
'We all respected her. She's been in government a long time,' said the staffer, who spoke on the condition that they not be named for fear of retaliation.
Dr. Jennifer Nuzzo, who directs the Pandemic Center at Brown University's School of Public Health, has known Monarez for at least a decade.
'She's a lifelong government scientist who has risen through the ranks to become a very senior leader,' Nuzzo said. 'She's loyal to serving the American people.'
They worked together when Monarez was detailed to the White House, where she worked on the US National Action Plan for Combating Antibiotic-Resistant Bacteria.
'She got into the nitty-gritty of a complex policy issue, but she was also able to bring together a really diverse set of stakeholders to provide input into that strategy,' Nuzzo said. 'I think that's a great example of what Susan does.'
Monarez has said she has three priorities for the CDC.
First, she said, she wants to improve trust in the agency and its recommendations. Next, she will focus on strengthening public health infrastructure by investing in tools to prevent, detect and respond to threats in near real-time. She pledged to collaborate with state and local public health departments to build a nationwide public health network. Finally, she said, she will work to create rapid, evidence-based responses to public health emergencies, with timely communication that is consistent and grounded in facts.
While these are worthy goals, Nuzzo said, her biggest worry is whether Monarez will be able to act independently, without political interference.
'You can't run an organization as important and large as the CDC if you need to get permission for everything that needs to be done,' Nuzzo added.
Dr. Richard Besser, a former acting director of the CDC, said in a statement that he looked forward to meeting Monarez to better understand her plans to lead the agency. Besser is now president and CEO of the Robert Wood Johnson Foundation.
'Dr. Monarez must not only lead the CDC – she must fight for it. Our nation's entire public health system depends on CDC having the tools it needs to respond to pandemics, reduce chronic disease, and address health inequities that continue to leave too many communities behind. That starts with a director willing to speak the truth, defend science, and stand up for the health of every American,' Besser said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Hims & Hers Health (NYSE:HIMS) Misses Q2 Revenue Estimates, Stock Drops 12%
Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market's revenue expectations in Q2 CY2025, but sales rose 72.6% year on year to $544.8 million. On the other hand, the company expects next quarter's revenue to be around $580 million, close to analysts' estimates. Its GAAP profit of $0.17 per share was 13% above analysts' consensus estimates. Is now the time to buy Hims & Hers Health? Find out in our full research report. Hims & Hers Health (HIMS) Q2 CY2025 Highlights: Revenue: $544.8 million vs analyst estimates of $550.8 million (72.6% year-on-year growth, 1.1% miss) EPS (GAAP): $0.17 vs analyst estimates of $0.15 (13% beat) Adjusted EBITDA: $82.24 million vs analyst estimates of $72.2 million (15.1% margin, 13.9% beat) The company reconfirmed its revenue guidance for the full year of $2.35 billion at the midpoint EBITDA guidance for the full year is $315 million at the midpoint, below analyst estimates of $319.4 million Operating Margin: 4.9%, up from 3.5% in the same quarter last year Free Cash Flow was -$69.43 million, down from $47.57 million in the same quarter last year Customers: 2.44 million, up from 2.37 million in the previous quarter Market Capitalization: $14 billion 'It's never been more clear that we are delivering exactly what millions of people have been waiting for: access to personalized, high-quality care that meets people where they are. From the momentum of our business to the results our customers are achieving, we are more confident than ever that our model is helping people optimize their health and realize the benefits of precision medicine,' said Andrew Dudum, co-founder and CEO. Company Overview Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE:HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, Hims & Hers Health grew its sales at an incredible 78.1% compounded annual growth rate. Its growth surpassed the average healthcare company and shows its offerings resonate with customers, a great starting point for our analysis. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Hims & Hers Health's annualized revenue growth of 68.3% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. We can better understand the company's revenue dynamics by analyzing its number of customers, which reached 2.44 million in the latest quarter. Over the last two years, Hims & Hers Health's customer base averaged 43.3% year-on-year growth. Because this number is lower than its revenue growth, we can see the average customer spent more money each year on the company's products and services. This quarter, Hims & Hers Health achieved a magnificent 72.6% year-on-year revenue growth rate, but its $544.8 million of revenue fell short of Wall Street's lofty estimates. Company management is currently guiding for a 44.4% year-on-year increase in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 28.5% over the next 12 months, a deceleration versus the last two years. Still, this projection is healthy and indicates the market sees success for its products and services. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating Margin Although Hims & Hers Health was profitable this quarter from an operational perspective, it's generally struggled over a longer time period. Its expensive cost structure has contributed to an average operating margin of negative 1.7% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. On the plus side, Hims & Hers Health's operating margin rose by 43.9 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming in on its more recent performance, we can see the company's trajectory is intact as its margin has also increased by 13.6 percentage points on a two-year basis. These data points are very encouraging and show momentum is on its side. In Q2, Hims & Hers Health generated an operating margin profit margin of 4.9%, up 1.4 percentage points year on year. This increase was a welcome development and shows it was more efficient. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Hims & Hers Health's full-year EPS flipped from negative to positive over the last five years. This is a good sign and shows it's at an inflection point. In Q2, Hims & Hers Health reported EPS at $0.17, up from $0.06 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Hims & Hers Health's full-year EPS of $0.80 to grow 4.4%. Key Takeaways from Hims & Hers Health's Q2 Results We enjoyed seeing Hims & Hers Health beat analysts' EPS expectations this quarter. We were also happy its customer base narrowly outperformed Wall Street's estimates. On the other hand, its EBITDA guidance for next quarter missed and its revenue fell slightly short of Wall Street's estimates. Overall, this quarter could have been better. The stock traded down 12% to $55.84 immediately after reporting. Should you buy the stock or not? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
Yahoo
3 minutes ago
- Yahoo
NYC air quality worsens again amid Canadian wildfire haze
NEW YORK — Hazy skies and low air quality returned to the five boroughs on Monday, as smoke from Canadian wildfires again created a gray scene in the New York skies. All of New York state and almost all of New England was under an air quality alert from the National Weather Service on Monday afternoon. The warning for New York City extended until midnight. 'Air quality is unhealthy for sensitive groups, including older adults, children, and people with heart or lung conditions,' NYC's emergency department wrote on social media. 'You may notice a faint smell of smoke, and low visibility conditions.' It has become a depressingly familiar story for New Yorkers in recent years. Smoke from uncontrolled wildfires in Canada, most of them in the province of Manitoba, has been carried south and east by common wind patterns. The worst air quality in recent years occurred in June 2023, when the smoke became so thick it created an orange haze over the city. However, the subpar air quality has returned to the city in each of the past two summers as well, including multiple times earlier this year. 'Limit outdoor activity, close windows, use air purifiers if available, and consider wearing a high-quality mask if you must go outside and are in a sensitive group,' NYC Emergency Management warned. New York was hardly alone in dealing with poor air quality on Monday. All of Maine, New Hampshire, Massachusetts, Rhode Island, Connecticut and Delaware, along with the majority of Vermont were also under air quality alerts. _____


CBS News
5 minutes ago
- CBS News
Annual March of Dimes Golf Classic in Ann Arbor raises money for families with premature babies
Dozens of golfers are teeing off their week at St. John's Resort in Plymouth, Michigan, for an important cause. The 44th annual March of Dimes Golf Classic is dedicated to raising money, conducting research, and providing support to families navigating life after a premature birth, one of its longest-running traditions. "Every year, we raise $25,000 and we bring 50 golfers from across the DuComb staff, across suppliers, and across our customer base as well," said Chris DuComb, president of W.C. DuComb Co. and supporter of March of Dimes. Participating in the tournament is a tradition that began with DuComb's uncle, who once managed the family business, and it continues in his honor. "My uncle Bill was born premature. He got involved in March of Dimes because of his personal connection. Since his passing in 2015, I took over the company about six years ago, and we've just continued supporting March of Dimes in Bill's legacy," DuComb said. While the event's location has changed throughout the decades, the mission hasn't. "We're fighting birth defects, preterm birth, infant mortality, we're fighting maternal mortality and post-partum. We want every baby born on time and healthy, and we want every mom healthy," said Stephanie Worth, executive director of March of Dimes Michigan. Worth says one in 10 babies in Michigan are born prematurely, and the money raised will go toward caring for them in the womb and after they're born. "So, we are fighting through all of those phases for moms and babies," Worth said. March of Dimes will also be hosting another fundraiser this fall.